Last reviewed · How we verify
Didanosine, Lamivudine, Nevirapine
Didanosine, Lamivudine, Nevirapine is a Antiretroviral combination (NRTI + NNRTI) Small molecule drug developed by Tuberculosis Research Centre, India. It is currently in Phase 3 development for HIV-1 infection.
This is a fixed-dose combination of three nucleoside/non-nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.
This is a fixed-dose combination of three nucleoside/non-nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA. Used for HIV-1 infection.
At a glance
| Generic name | Didanosine, Lamivudine, Nevirapine |
|---|---|
| Sponsor | Tuberculosis Research Centre, India |
| Drug class | Antiretroviral combination (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Didanosine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that are incorporated into the growing viral DNA chain, causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to and inhibits reverse transcriptase. Together, they provide complementary mechanisms to suppress HIV replication.
Approved indications
- HIV-1 infection
Common side effects
- Peripheral neuropathy
- Pancreatitis
- Rash
- Hepatotoxicity
- Nausea
- Diarrhea
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- A Prospective Cohort of Children With HIV Infection
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (PHASE3)
- A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses (PHASE1)
- A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment (PHASE1)
- Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Didanosine, Lamivudine, Nevirapine CI brief — competitive landscape report
- Didanosine, Lamivudine, Nevirapine updates RSS · CI watch RSS
- Tuberculosis Research Centre, India portfolio CI
Frequently asked questions about Didanosine, Lamivudine, Nevirapine
What is Didanosine, Lamivudine, Nevirapine?
How does Didanosine, Lamivudine, Nevirapine work?
What is Didanosine, Lamivudine, Nevirapine used for?
Who makes Didanosine, Lamivudine, Nevirapine?
What drug class is Didanosine, Lamivudine, Nevirapine in?
What development phase is Didanosine, Lamivudine, Nevirapine in?
What are the side effects of Didanosine, Lamivudine, Nevirapine?
What does Didanosine, Lamivudine, Nevirapine target?
Related
- Drug class: All Antiretroviral combination (NRTI + NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Tuberculosis Research Centre, India — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: Didanosine, Lamivudine, Nevirapine vs similar drugs
- Pricing: Didanosine, Lamivudine, Nevirapine cost, discount & access